Brief: Transcenta Says Global Clinical Collaboration With Bristol Myers Squibb To Evaluate Tst001 In With Opdivo
22/03/2022 01:21
March 22 (Reuters) - Transcenta Holding Limited 6628.HK :
* GLOBAL CLINICAL COLLABORATION WITH BRISTOL MYERS SQUIBB TO
EVALUATE TST001 IN WITH OPDIVO
Further company coverage: 6628.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcenta Holding
See all newsBrief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
Brief: Transcenta Holding Says Unit To Sell CDMO Assets For RMB190.0 Million
Brief: Transcenta Holding To Revert Assets To Lilly For $4 Million Cash
Brief: Transcenta Therapeutics Appoints Dr. Christopher Hwang As Head Of Global Partnerships For Hicb Platform
Brief: Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.